Managing Depression during Hepatitis C Treatment

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Canadian journal of psychiatry. Revue canadienne de psychiatrie

• Publication date

  2009-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/070674370905400906PMID 19751550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders.

  2008cited by this paper
• High frequency of unrecognized mental disorders in HCV-infected patients.

  2008cited by this paper
• Preventing Relapse of Major Depression During Interferon-α Therapy for Hepatitis C—A Pilot Study

  2007cited by this paper
• Hepatitis C treatment in “difficult‐to‐treat” psychiatric patients with pegylated interferon‐alpha and ribavirin: Response and psychiatric side effects

  2007cited by this paper
• Quetiapine-induced leucopenia and thrombocytopenia.

  2007influential reference
• Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders.

  2007cited by this paper
• Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.

  2007cited by this paper
• A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.

  2007cited by this paper
• Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C.

  2007cited by this paper
• Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort.

  2007cited by this paper
• HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment.

  2007cited by this paper
• Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life.

  2007cited by this paper
• Management of chronic hepatitis C: consensus guidelines.

  2007cited by this paper
• Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-&agr; and ribavirin: results from a randomized, placebo-controlled, double-blind trial

  2007cited by this paper
• Depression following pegylated interferon-alpha: characteristics and vulnerability.

  2007cited by this paper
• Paroxetine for prevention of depressive symptoms induced by interferon‐alpha and ribavirin for hepatitis C

  2007cited by this paper
• The Successful Use of Electroconvulsive Therapy in a Patient With Interferon-Induced Psychotic Depression

  2007influential reference
• Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol.

  2007cited by this paper
• Selective serotonin reuptake inhibitors in the context of hepatitis C infection: reexamining the risks of bleeding.

  2007cited by this paper
• Modafinil’s Use in Combating Interferon-Induced Fatigue

  2007cited by this paper
• Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study

  2007influential reference
• Manic episode associated with citalopram therapy for interferon-induced depression in a patient with chronic hepatitis C infection.

  2007cited by this paper
• Integrated Psychiatric/Medical Care in a Chronic Hepatitis C Clinic: Effect on Antiviral Treatment Evaluation and Outcomes

  2006cited by this paper
• Management and Treatment of Hepatitis C Viral Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office

  2006cited by this paper
• Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment.

  2006influential reference
• Clinical Practice and Epidemiology in Mental Health Association of Chronic Hepatitis C with Major Depressive Disorders: Irrespective of Interferon-alpha Therapy

  2006cited by this paper
• Case Report of 3 Patients with Severe Mental Illness and Chronic Hepatitis C Virus Infection Treated with Interferon-Alpha

  2006cited by this paper
• Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis.

  2006cited by this paper
• Depressive symptoms and physical/mental functioning with interferon/ribavirin treatment of posttransplant recurrent hepatitis C.

  2006cited by this paper
• Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study.

  2006cited by this paper
• Prophylactic SSRI during interferon alpha re‐therapy in patients with chronic hepatitis C and a history of interferon‐induced depression

  2005cited by this paper
• Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-α treatment

  2005cited by this paper
• Irritability Rather Than Depression During Interferon Treatment Is Linked to Increased Tryptophan Catabolism

  2005cited by this paper
• Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

  2005cited by this paper
• IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity

  2005influential reference
• Neuropsychiatric Adverse Effects of Interferon-α

  2005cited by this paper
• Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.

  2005cited by this paper
• Depression during therapy with interferon α - How long should an antidepressant treatment last? A case report

  2005cited by this paper
• Interferon-induced depression: prevalence and management.

  2005cited by this paper
• Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

  2005cited by this paper
• Sertraline- and mirtazapine-induced severe neutropenia.

  2005influential reference
• Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

  2005cited by this paper
• Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection

  2005cited by this paper
• Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.

  2005cited by this paper
• Major depressive disorder with psychotic features induced by interferon-α treatment for hepatitis C in a polydrug abuser

  2005cited by this paper
• Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors.

  2005cited by this paper
• Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?

  2005cited by this paper
• Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

  2005cited by this paper
• Treatment of recurrent hepatitis C after liver transplantation.

  2005cited by this paper
• Depression during therapy with interferon alpha--how long should an antidepressant treatment last?

  2005cited by this paper
• Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser.

  2005cited by this paper
• Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

  2005cited by this paper
• Bupropion for Treatment of Interferon-Induced Depression

  2004cited by this paper
• Diagnosis, management, and treatment of hepatitis C

  2004cited by this paper
• Plasma levels of citalopram in depressed patients with hepatitis C.

  2004cited by this paper
• Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changes

  2004cited by this paper
• Psychopharmacological Treatment of Depression, Anxiety, Irritability and Insomnia in Patients Receiving Interferon-α: a Prospective Case Series and a Discussion of Biological Mechanisms

  2004cited by this paper
• Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C.

  2004cited by this paper
• Screening for depressive symptoms among HCV-infected injection drug users: Examination of the utility of the CES-D and the beck depression inventory

  2004cited by this paper
• Morbidity of Chronic Hepatitis C as Seen in a Tertiary Care Medical Center

  2004cited by this paper
• Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C.

  2004cited by this paper
• Drug-Induced Depression: A Systematic Review to Inform Clinical Practice

  2004cited by this paper
• Association of interferon-α-induced depression and improved treatment response in patients with hepatitis C

  2004cited by this paper
• Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.

  2004cited by this paper
• A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

  2003cited by this paper
• Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study.

  2003cited by this paper
• Prevalence of hepatitis C among psychiatric patients in the public sector.

  2003cited by this paper
• A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients.

  2003cited by this paper
• Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

  2003cited by this paper
• Mirtazapine for the treatment of interferon-induced psychopathology.

  2003cited by this paper
• Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.

  2002cited by this paper
• Interferon alpha (IFNα) and psychiatric syndromes: A review

  2002cited by this paper
• Interferon alpha (IFNalpha) and psychiatric syndromes: a review.

  2002cited by this paper
• Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus.

  2002cited by this paper
• Interferon-induced depression treated with citalopram.

  2002cited by this paper
• Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions

  2002cited by this paper
• Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

  2002cited by this paper
• Psychiatric disorders among veterans with hepatitis C infection.

  2002cited by this paper
• Spectrum of disease in U.S. veteran patients with hepatitis C

  2002cited by this paper
• Increased Depressive Ratings in Patients With Hepatitis C Receiving Interferon-α–Based Immunotherapy Are Related to Interferon-α–Induced Changes in the Serotonergic System

  2002cited by this paper
• A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C

  2002cited by this paper
• Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness.

  2001cited by this paper
• Paroxetine for the prevention of depression induced by high-dose interferon alfa.

  2001cited by this paper
• Psychiatric comorbidity among hepatitis C-positive patients.

  2001cited by this paper
• Lowered Serum Dipeptidyl Peptidase IV Activity is Associated with Depressive Symptoms and Cytokine Production in Cancer Patients Receiving Interleukin-2-Based Immunotherapy

  2001cited by this paper
• Influence of psychiatric diagnoses on interferon-α treatment for chronic hepatitis C in a veteran population

  2001cited by this paper
• Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.

  2000cited by this paper
• Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis

  2000cited by this paper
• Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo.

  2000influential reference
• Sertraline treatment of interferon‐alfa‐induced depressive disorder

  2000cited by this paper
• Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

  1999cited by this paper
• Psychotic depression occurring after stopping interferon-alpha.

  1999influential reference
• Cytokines, "depression due to a general medical condition," and antidepressant drugs.

  1999influential reference
• Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders.

  1999cited by this paper
• Five cases of interferon-alpha-induced depression treated with antidepressant therapy.

  1999cited by this paper
• Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders

  1999cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Effects of interferon-α, interferon-γ and cAMP on the transcriptional regulation of the serotonin transporter

  1998cited by this paper
• Hepatitis C virus and depression in drug users

  1998cited by this paper
• Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter.

  1998cited by this paper

• The janus face of serotonin: Regenerative promoter and chronic liver disease aggravator

  2024cites this paper
• Pharmacological interventions for depression in adults with chronic hepatitis B or C

  2022cites this paper
• The role of circulatory systemic environment in predicting interferon-alpha–induced depression: The neurogenic process as a potential mechanism

  2019cites this paper
• Retinopathy Associated with Adjuvant Interferon in a Patient with Malignant Melanoma: A Case Report and Review of the Literature

  2019cites this paper
• Efficacy and safety of telaprevir with natural human interferon‐β and ribavirin in Japanese chronic hepatitis C patients with depression

  2018cites this paper
• Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions

  2018cites this paper
• Neuropsychiatric Complications of Injection-Associated Diseases: HIV and Hepatitis C

  2017cites this paper
• Biomedical and clinical markers, illness perceptions, coping, benefit finding, adjustment, and treatment outcomes in hepatitis C: a self-regulatory, biopsychosocial model.

  2017cites this paper
• Sexual behaviour of HIV-diagnosed men who have sex with men in England in the era of effective antiretroviral therapy: results from the ASTRA study

  2017cites this paper
• Prevalence and Risk Factors of Depression and Anxiety in Hepatitis C Patients Receiving Pegylated Interferon Alpha (IFN-a)

  2017cites this paper
• A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz

  2016cites this paper
• Co-occurring Depression, Chronic Pain and Substance Use Disorders in People with Hepatitis C

  2016cites this paper
• Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)‐coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]

  2016cites this paper
• TLR4 signaling in VTA dopaminergic neurons regulates impulsivity through tyrosine hydroxylase modulation

  2016cites this paper
• Engagement in Group Psychotherapy Among Marginalized Individuals With Hepatitis C

  2016cites this paper
• Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment

  2016cites this paper
• Fluoxetine regulates cell growth inhibition of interferon-α.

  2016cites this paper
• PSYCHIC STRESS IN C HEPATITIS VIRUS INFECTION

  2016cites this paper
• Hepatitis C Virus and Schizophrenia: Expanding the Role of the Community Psychiatrist.

  2016cites this paper
• Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support.

  2015cites this paper
• Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.

  2015cites this paper
• Major depressive disorder and generalized anxiety disorder and response to treatment in hepatitis C patients in Egypt

  2015cites this paper
• Longitudinal Effects of Selective Serotonin Reuptake Inhibitor Therapy and Cytokine-Related Depression on Hepatitis C Viral Logs During Antiviral Therapy

  2014cites this paper
• Inflammation-induced depression : Studying the role of proinflammatory cytokines in anhedonia

  2014cites this paper
• Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways.

  2014cites this paper
• Awareness of Biologically Confirmed HCV Among a Community Residing Sample of Drug Users in Baltimore City

  2014cites this paper
• Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis.

  2014cites this paper
• Birth Cohort Testing for Hepatitis C Virus: Implications for Clinical Social Workers in Health Care Settings

  2013influential citation
• Psychiatric treatment considerations with direct acting antivirals in hepatitis C

  2013cites this paper
• Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China

  2013cites this paper
• Strategies for Treating Depression in Patients with Hepatitis C: Psychiatric Symptoms Can Precede Infection or Be Caused by HCV Treatments

  2013cites this paper
• Cognitive, biological and psychosocial factors predicting interferon-alpha-induced depression

  2013influential citation
• The role of inflammatory cytokines in suicidal behavior: a systematic review.

  2013cites this paper
• Psychiatric clearance for patients started on interferon-alpha-based therapies.

  2013cites this paper
• Hepatitis C treatment and erotomania.

  2012cites this paper
• Symptomatic Treatment of Interferon-&agr;–Induced Depression in Hepatitis C: A Systematic Review

  2012influential citation
• Glycogen synthase kinase‐3β is critical for Interferon‐α‐induced serotonin uptake in human Jurkat T cells

  2012influential citation
• Influence of Healthcare-Associated Factors on the Efficacy of Hepatitis C Therapy

  2012cites this paper
• Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.

  2012cites this paper
• Assessing Psychiatric Adverse Effects during Clinical Drug Development

  2012cites this paper
• Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance

  2012cites this paper
• [Depression in patients with chronic hepatitis C during the antiviral treatment: a clinical and psychopathological qualification and a nosological interpretation].

  2012cites this paper
• Utilizing genomic polymorphisms to personalize hepatitis C therapies

  2012cites this paper
• Psychische Störungen bei somatischen Krankheiten

  2011cites this paper
• The acid sphingomyelinase inhibitors block interferon-α-induced serotonin uptake via a COX-2/Akt/ERK/STAT-dependent pathway in T cells.

  2011cites this paper
• The risk of depression in chronic obstructive pulmonary disease

  2011cites this paper
• Frequency of depression in chronic Hepatitis C naïve patients

  2011cites this paper
• [Use of anxiolytics and antidepressants before and after treatment with interferon-alpha and ribavirin in patients with hepatitis C].

  2011cites this paper
• Depression comorbidity in patients with chronic hepatitis C and its possible relation to treatment outcome

  2011cites this paper
• Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C.

  2011cites this paper
• Literature systematic review on the ophthalmological side effects of interferons.

  2011cites this paper
• Management of Hepatitis C Antiviral Therapy Adverse Effects

  2010cites this paper
• Management of Psychiatric Disease in Hepatitis C Treatment Candidates

  2010influential citation
• Title Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response Permalink

  2010cites this paper
• Antidepressant pretreatment and symptomatic treatment in interferon treatment.

  2010cites this paper
• Treatment of Chronic Hepatitis C in Children

  2010cites this paper
• Trouble bipolaire et cancer : particularités de la prise en charge

  2010cites this paper
• Treatment of psychological co-morbidities in common gastrointestinal and hepatologic disorders.

  2010cites this paper
• Severe Depression, Suicide Attempts, and Ideation During the Use of Interferon Beta by Patients With Multiple Sclerosis

  2010cites this paper
• Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals

  2010cites this paper
• Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response

  2010cites this paper
• Individualisation of antiviral therapy for chronic hepatitis C

  2010cites this paper
• Antidepressant Pretreatment and Symptomatic Treatment in Interferon Treatment

  2010cites this paper
• Depresión y ansiedad inducida por interferón pegilado y ribavirina en la

  2009cites this paper
• Depresión y ansiedad inducida por interferón pegilado y ribavirina en la hepatitis crónica C

  2009cites this paper
• News and Current Affairs

  2008cites this paper